TGFB1 and neoplasm: Potential strategies for development of novel therapies would be either to target CAF-derived tumor promotion and immunosuppressive ligands, such as IL-6 and TGFβ, or to inhibit subtype-specific signaling pathways that would destroy specific CAF populations [18,99,100].